This is the version of the explanation I wish somebody had given me, written down before I forget what confused me. It is about cost and coverage, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.
The condition it depends on
Coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.
What I am not sure about
What I am after is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. Happy to be told the question itself is wrong.
InsuranceTom said:Denials are usually procedural rather than clinical, and the order that works reflects that.
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $287/month (eating less)
- Restaurants: SAVED $157/month (fewer meals out)
- Alcohol: SAVED $107/month (stopped drinking)
- Life insurance: Premium REDUCED by $37/month (lower BMI)
- Copays: SAVED $57/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
InsuranceTom said:Denials are usually procedural rather than clinical, and the order that works reflects that.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.PeteFamMed said:The affordability discussion here usually stops at individual tactics.
Dr.PeteFamMed said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.
BariatricNurseD said:Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $287/month (eating less) Restaurants: SAVED $157/month…
Adding a me-too, because a thread of one person's experience is not much use.